Patents by Inventor Hartmut Schetters

Hartmut Schetters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6630350
    Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: October 7, 2003
    Assignee: Roche Diagnostics GmbH
    Inventors: Christa Hubner-Parajsz, Hartmut Schetters, Rosemarie Kientsch-Engel, Thomas Meier, Martin Kaufmann, Andreas Gallusser, Rolf Deeg
  • Publication number: 20030073141
    Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.
    Type: Application
    Filed: July 2, 2002
    Publication date: April 17, 2003
    Inventors: Christa Hubner-Parajsz, Hartmut Schetters, Rosemarie Kientsch-Engel, Thomas Meier, Martin Kaufmann, Andreas Gallusser, Rolf Deeg
  • Patent number: 5248593
    Abstract: The present invention provides an immunological process for the determination of the luteinizing hormone (LH), wherein at least one monoclonal antibody is used which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.The present invention also provides a reagent for the determination of the luteinizing hormone, wherein it contains at least one monoclonal antibody which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.Furthermore, the present invention provides a monoclonal antibody against the luteinizing hormone and a process and a hybridoma cell line for producing it.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: September 28, 1993
    Assignee: Boehringer Mannheim GmbH
    Inventors: Christa Hubner-Parajsz, Hartmut Schetters, Helmut Lenz, Klaus Erler
  • Patent number: 5094940
    Abstract: A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behaviour to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample.
    Type: Grant
    Filed: July 7, 1989
    Date of Patent: March 10, 1992
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hartmut Schetters, Josef Endl, Winfried Albert
  • Patent number: 4876189
    Abstract: A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behavior to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample.
    Type: Grant
    Filed: November 5, 1986
    Date of Patent: October 24, 1989
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hartmut Schetters, Josef Endl, Winfried Albert
  • Patent number: 4762783
    Abstract: The present invention provides an immunological process for the determination of the follicle-stimulating hormone (FSH), wherein there is used at least one monoclonal antibody which is directed specifically against FSH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.The present invention also provides a reagent for the determination of the follicle-stimulating hormone, wherein it contains at least one monoclonal antibody which is directed against FSH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.Furthermore, the present invention provides a monoclonal antibody against the follicle-stimulating hormone and a process and a hybridoma cell line for producing it.
    Type: Grant
    Filed: February 27, 1986
    Date of Patent: August 9, 1988
    Assignee: Boehringer Mannheim GmbH
    Inventors: Christa Hubner-Parajsz, Hartmut Schetters, Helmut Lenz, Klaus Erler